KOD News and Press, Kodiak Sciences Inc From 05/08/22

ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT, CAPL, CARA, CARG, CHMI, CLAR, CLOV, CNNE, CSTL, OTCPK:CURLF, DDD, DHT, DNB, ENTA, EQH, EVBG, FCRD, FF, FGEN, FLL, ...

Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences PR Newswire PALO ALTO, Calif. , April 29, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A sharp spike in bond yields pressured growth stocks and ...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Blue Sky potential due to potential blockbuster candidates with a differentiated mechanism of action. Ocular is working to leverage its proprietary technology platform to optimize drug delivery for additional eye diseases. In the second half of the year, the important data release...

Karyopharm Therapeutics (NASDAQ:KPTI) -29% after US Regulatory update on Selinexor in advanced or recurrent endometrial cancer. GoHealth (NASDAQ:GOCO) -24% on expecting Q4 revenue below estimates. Bright Health (NYSE:BHG) -10% on Q4 earnings release. Telefonaktie...

Kodiak Sciences press release (NASDAQ:KOD): Q4 GAAP EPS of -$1.79 misses by $0.44. Ended the fourth quarter of 2021 with $731.5 million of cash and cash equivalents. For further details see: Kodiak Sciences GAAP EPS of -$1.79 misses by $0.44

Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , March 1, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, de...

Lead asset KSI-301 is being tested in six pivotal trials in retinal diseases including wet AMD, diabetic macular edema, retinal vein occlusion and non-proliferative diabetic retinopathy. Topline wet AMD data was released and KSI-301 failed to show non-inferiority against standard of c...

Stocks recorded another day of losses on Wednesday, weighed down by continued worries about tension with Russia and lingering fear about rising interest rates. The Nasdaq led the decline with a slide of 2.6%, as speculative names saw the most aggressive selling.  Meanwhile, the S&P 5...